Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, ...
ORIC Pharmaceuticals, Inc. announced its clinical development plans for its lead programs, ORIC-944 and ORIC-114, while reporting financial results for the first quarter of 2025. The company presented ...
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...
Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...
Researchers have developed a three-step plan to support those burdened by the intense fear of cancer returning. This plan offers a consistent, streamlined approach to managing recurrence anxiety, ...
This podcast from the 2023 IO360º conference focuses on key learnings from the full clinical development pathway for approved autologous cell therapy products, from first-in-human, through launch, to ...
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and ...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), and BeiGene, Ltd ...
Kymera Therapeutics has announced that Sanofi will advance their next-generation oral IRAK4 degrader, KT-485, into clinical testing, while opting not to pursue KT-474. Preclinical studies indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results